Finance

Lists
P8A:SGX
Cordlife Group Ltd
0,12 SGD
0,00%
(0,00) 1D
12 հոկ, 09:49:20 GMT+8  ·   SGD
All symbols
SymbolPriceChange% Change
Generating top insights for P8A...
Mkt. cap
32,37 մլն
Avg. vol.
1,22 հզր
Volume
0,00
52-wk high
0,26 SGD
52-wk low
0,10 SGD
EPS
-0,04 SGD
Shares outstanding
267,53 մլն
No. of employees
111
Mkt. cap
32,37 մլն
Avg. vol.
1,22 հզր
Volume
0,00
52-wk high
0,26 SGD
52-wk low
0,10 SGD
EPS
-0,04 SGD
Shares outstanding
267,53 մլն
No. of employees
111
News stories
From web sources and news partners
Profile
Cordlife Group Limited, is a consumer health company incorporated in May 2001 and a provider of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012. Cordlife Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six markets including Singapore, Hong Kong, India, Indonesia, and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services. Cordlife's stem cell processing and storage facilities in Singapore, Hong Kong, India, Indonesia, the Philippines and Malaysia were accredited by AABB until 2024 when its accreditation was withdrawn. In November 2023, the Ministry of Health of Singapore revealed that Cordlife Group had exposed cryopreserved cord blood units at suboptimal temperatures, damaging the cord blood units belonging to at least 2,150 clients and rendering them unsuitable for stem cell transplant purposes. Wikipedia
About Cordlife Group Ltd
CEOYiu Pang Fai
Employees111
Founded02 մյս, 2001 թ.
Headquarters-
SectorHealth care provider
Previous reportsAll values in SGD
Loading Previous Earnings...
Revenue
Net income
All values in SGD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
10,21 մլն
9,46 մլն
8,99 մլն
8,30 մլն
Cost of goods sold
4,16 մլն
4,05 մլն
3,78 մլն
3,44 մլն
Cost of revenue
4,16 մլն
4,05 մլն
3,78 մլն
3,44 մլն
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9,42 մլն
10,52 մլն
7,60 մլն
6,41 մլն
Operating expense
9,29 մլն
10,41 մլն
7,47 մլն
6,36 մլն
Total operating expenses
13,45 մլն
14,46 մլն
11,25 մլն
9,80 մլն
Operating income
-3,24 մլն
-5,00 մլն
-2,26 մլն
-1,50 մլն
Other non operating income
-
-
-
-
EBT including unusual items
-2,33 մլն
-4,30 մլն
-1,70 մլն
-873,00 հզր
EBT excluding unusual items
-2,33 մլն
-4,38 մլն
-1,70 մլն
-873,00 հզր
Income tax expense
149,00 հզր
1,26 մլն
19,00 հզր
64,00 հզր
Effective tax rate
-6,39%
-29,22%
-1,12%
-7,33%
Other operating expenses
-133,00 հզր
-111,00 հզր
-132,00 հզր
-54,00 հզր
Net income
-2,48 մլն
-5,55 մլն
-1,72 մլն
-936,00 հզր
Net profit margin
-24,32%
-58,72%
-19,13%
-11,28%
Earnings per share
-
-
-
-
Interest and investment income
642,00 հզր
589,00 հզր
565,00 հզր
587,00 հզր
Interest expense
-27,00 հզր
-34,00 հզր
-28,00 հզր
-77,00 հզր
Net interest expenses
615,00 հզր
555,00 հզր
537,00 հզր
510,00 հզր
Depreciation and amortization charges
-
-
-
-
EBITDA
-2,17 մլն
-4,29 մլն
-1,33 մլն
-621,00 հզր
Gain or loss from assets sale
1,00 հզր
220,00 հզր
5,00 հզր
4,00 հզր
AI content may include mistakes. Learn more
Google Apps